LINFOMAS Y TRASPLANTES
Hospital Universitari de Bellvitge
l'Hospitalet de Llobregat, EspañaPublications en collaboration avec des chercheurs de Hospital Universitari de Bellvitge (34)
2024
-
Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial
Bone Marrow Transplantation
-
Treatment outcomes in patients with large B-cell lymphoma after progression to chimeric antigen receptor T-cell therapy
HemaSphere, Vol. 8, Núm. 5
2023
-
Extranodal natural killer/T-cell lymphoma nasal type in a western population: Molecular profiling identifies new therapeutic targets
American Journal of Hematology
-
Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study
Transplantation and Cellular Therapy, Vol. 29, Núm. 12, pp. 747.e1-747.e10
-
Peripheral T-cell lymphoma with a T follicular-helper phenotype: A different entity? Results of the Spanish Real-T study
British Journal of Haematology, Vol. 203, Núm. 2, pp. 182-193
-
Unraveling the genetics of transformed splenic marginal zone lymphoma
Blood Advances, Vol. 7, Núm. 14, pp. 3695-3709
2022
-
A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression
Blood Advances, Vol. 6, Núm. 21, pp. 5763-5773
-
Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation
British Journal of Haematology, Vol. 196, Núm. 1, pp. 146-155
-
Detection of early seeding of Richter transformation in chronic lymphocytic leukemia
Nature Medicine, Vol. 28, Núm. 8, pp. 1662-1671
-
Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications
Histopathology, Vol. 81, Núm. 6, pp. 826-840
-
Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 11, pp. 1196-1205
-
Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma
Blood Advances
-
The role of PSMA radioligands in the diagnosis and treatment of prostate carcinoma
Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 41, Núm. 2, pp. 126-135
2021
-
Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative
Annals of Hematology, Vol. 100, Núm. 3, pp. 825-830
-
COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey
Leukemia, Vol. 35, Núm. 10, pp. 2885-2894
-
Clinical and pathological characteristics of peripheral T-cell lymphomas in a Spanish population: a retrospective study
British Journal of Haematology, Vol. 192, Núm. 1, pp. 82-99
-
Peripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markers
Blood Advances, Vol. 5, Núm. 24, pp. 5588-5598
-
Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma
Cancer Medicine, Vol. 10, Núm. 10, pp. 3214-3223
2020
-
Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study
Journal of Neuro-Oncology, Vol. 148, Núm. 3, pp. 545-554